tDCS in Adults With ASD and/or ADHD Without Intellectual Disability
Ensayo clínico Fase 1 de tDCS en Adultos Con TEA y/o TDAH Sin Discapacidad Intelectual
1 other identifier
interventional
25
1 country
1
Brief Summary
The goal of this clinical trial is to learn about the safety and tolerability of transcranial direct current stimulation (tDCS) combined with cognitive training in adults with Autism Spectrum Disorder (ASD) and/or Attention-Deficit/Hyperactivity Disorder (ADHD). The main question it aims to answer is: Is tDCS safe and well-tolerated in adults with ASD and/or ADHD? Researchers will compare active tDCS to a sham (placebo-like) stimulation to evaluate safety and tolerability. Participants will: Receive either active or sham tDCS for 20 minutes daily over 10 consecutive workdays Undergo stimulation with the anode placed at F3 and the cathode at Fp2 Complete daily cognitive training exercises using the NeuronUP platform during stimulation Attend baseline and follow-up assessments to monitor for any side effects or discomfort related to the intervention
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Nov 2022
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 7, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 19, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
January 19, 2024
CompletedFirst Submitted
Initial submission to the registry
April 8, 2025
CompletedFirst Posted
Study publicly available on registry
April 27, 2025
CompletedAugust 1, 2025
July 1, 2025
1.2 years
April 8, 2025
July 29, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Participants will be monitored for adverse events, side effects (e.g., headache, skin irritation, fatigue), and dropout rates. This will be assessed through participant self-report, clinician observation, and standardized side effect checklists administered during and after each session. The outcome will help determine whether daily tDCS paired with cognitive training is safe and acceptable for adults with ASD and/or ADHD.
Throughout the 10-day intervention period and at follow-up (up to 2 weeks post-intervention)
Study Arms (2)
Active tDCS + Cognitive Training
ACTIVE COMPARATORParticipants in this arm will receive anodal transcranial direct current stimulation (tDCS) at 2 mA for 20 minutes per session over 10 consecutive workdays. The anode will be placed over the left dorsolateral prefrontal cortex (F3) and the cathode over the right frontopolar cortex (Fp2) using the 10-20 EEG system. Stimulation will be administered concurrently with cognitive training using the NeuronUP platform, which includes tasks targeting attention, memory, and executive function.
Sham tDCS + Cognitive Training
SHAM COMPARATORParticipants in this arm will undergo the same setup and procedures as the active tDCS group but will receive sham stimulation, which mimics the sensation of tDCS without delivering current beyond the initial ramp-up/down. They will also complete cognitive training with the NeuronUP platform during each session.
Interventions
This intervention involves non-invasive brain stimulation using transcranial direct current stimulation (tDCS) delivered via saline-soaked sponge electrodes. The anode is placed at F3 (left dorsolateral prefrontal cortex) and the cathode at Fp2 (right frontopolar cortex), according to the international 10-20 EEG system. A 2 mA current is applied for 20 minutes per session, administered once daily on 10 consecutive workdays. During stimulation, participants engage in cognitive training using the NeuronUP platform, which provides structured, interactive tasks designed to train executive function, attention, and working memory. This combination aims to enhance neural plasticity by pairing neuromodulation with cognitive engagement.
The sham condition mimics the active setup but delivers only brief ramp-up/down stimulation, producing the initial sensation without sustained current.
The cognitive training intervention in this study is delivered through NeuronUP, a digital platform offering evidence-based cognitive stimulation activities. This intervention targets core cognitive domains such as working memory, attention, and executive function through personalized, interactive tasks. What distinguishes this approach is NeuronUP's extensive library of over 10,000 activities, its ability to tailor difficulty levels in real time based on individual performance, and the inclusion of functional tasks that mirror real-life scenarios. Unlike other interventions, NeuronUP also enables therapist-guided customization, allowing for individualized treatment plans that evolve with participant progress, ensuring both relevance and ecological validity.
Eligibility Criteria
You may qualify if:
- Adults aged 18 to 55 years
- Clinical diagnosis of Autism Spectrum Disorder (ASD) and/or Attention-Deficit/Hyperactivity Disorder (ADHD) confirmed via medical records or structured clinical interview
- Able to provide informed consent
- Fluent in the language used for assessments and cognitive training tasks
- Stable medication regimen (if applicable) for at least 4 weeks prior to enrollment
- Willing and able to attend 10 consecutive weekday sessions and follow-up assessment
You may not qualify if:
- History of epilepsy, seizures, or significant neurological disorder (e.g., traumatic brain injury, stroke)
- Current diagnosis of psychotic disorder or bipolar disorder
- Presence of metal implants in the head (excluding dental work), pacemaker, or other contraindications to tDCS
- Current substance use disorder (within past 6 months)
- Pregnant or planning to become pregnant during the study period
- Participation in another intervention study within the last 30 days
- Any condition that, in the opinion of the investigators, may make participation unsafe or interfere with study procedures
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hospital Universitari Vall d'Hebron
Barcelona, Barcelona, 08035, Spain
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 8, 2025
First Posted
April 27, 2025
Study Start
November 7, 2022
Primary Completion
January 19, 2024
Study Completion
January 19, 2024
Last Updated
August 1, 2025
Record last verified: 2025-07
Data Sharing
- IPD Sharing
- Will not share